Xtant Medical Holdings Inc is a medical devices business based in the US. Xtant Medical shares (XTNT) are listed on the NYSE MKT and all prices are listed in US Dollars. Xtant Medical employs 116 staff and has a trailing 12-month revenue of around $56 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $0.64 |
|---|---|
| 52-week range | $0.43 - $1.27 |
| 50-day moving average | $0.55 |
| 200-day moving average | $0.60 |
| Wall St. target price | $1.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.09 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.64 from 2022-09-26
| 1 week (2022-09-20) | -1.54% |
|---|---|
| 1 month (2022-08-26) | 25.49% |
| 3 months (2022-06-27) | 30.61% |
| 6 months (2022-03-25) | -4.48% |
| 1 year (2021-09-27) | -45.30% |
|---|---|
| 2 years (2020-09-25) | -15.79% |
| 3 years (2019-09-27) | 2.82 |
| 5 years (2017-09-27) | 0.7413 |
| Revenue TTM | $56 million |
|---|---|
| Gross profit TTM | $32.5 million |
| Return on assets TTM | -6.99% |
| Return on equity TTM | -25.83% |
| Profit margin | -14.31% |
| Book value | $0.32 |
| Market capitalisation | $61.9 million |
TTM: trailing 12 months
We're not expecting Xtant Medical to pay a dividend over the next 12 months.
Xtant Medical's shares were split on a 1:12 basis on 13 February 2018. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Xtant Medical shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Xtant Medical shares which in turn could have impacted Xtant Medical's share price.
Over the last 12 months, Xtant Medical's shares have ranged in value from as little as $0.43 up to $1.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Xtant Medical's is 1.0092. This would suggest that Xtant Medical's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.